ClinicalTrials.gg
CompletedNCT06593587Updated Feb 9, 2026Results posted

A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Older Adults in Korea

A Phase 3 interventional study of RSVpreF Vaccine and Placebo in Respiratory Syncytial Virus, sponsored by Pfizer. Completed at 16 sites in South Korea. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-09.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
378
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Respiratory Tract Infections by Pfizer — 2 open to participants now, 3 under way, 2 of them phase 3. Respiratory Tract Infections · Pfizer.

Enrollment
8th of 18
378 · median 309
Started
2024
with 3 others
Phase 3
7 of 23
2 open now
Registered
19th of 23
by date

Among the 23 studies in Respiratory Tract Infections by Pfizer, this one is the 8th largest by enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2024, is one of 7 in phase 3, and was the 19th registered.

Respiratory Tract Infections

753 studies on the registry are indexed under Respiratory Tract Infections; 114 are open to participants now.

Browse Respiratory Tract Infections studies →

Open to participants now

2 of the 23 studies in Respiratory Tract Infections by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 74 Respiratory Tract Infections studies recruiting now, 35 (47%) set no upper age limit and 31 (42%) stop at 75 or younger; 34 take children under 18; 25 take healthy volunteers.

This study: 60 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Respiratory Tract Infections by Pfizer, or all of them as a file.
02

Study summary

The goal of this clinical trial is to quantify the immune response in older Korean adults after a RSVpreF vaccination. It will also learn about the safety and tolerability of RSVpreF vaccination. The main questions it aims to answer are:

What local reactions and systemic events do participants have after a RSVpreF vaccination? What medical problems do participants have after a RSVpreF vaccination? Researchers will compare RSVpreF to a placebo (a look-alike substance that contains no RSVpreF) to see if RSVpreF is safe and well tolerated. It will also examine the change in antibody levels (immune responses) before and after vaccination.

Participants will:

Receive the RSVpreF vaccination or a placebo injection once at Visit 1. Visit the clinic a month later for a checkup and tests. Receive a phone call 1 week after vaccination, and 2 months after vaccination, for health checks.

Keep a diary of their symptoms for 7 days after vaccination.

Read the detailed description

This is a Phase 3, randomized, double-blinded, placebo-controlled, multicenter trial to describe the safety, tolerability, and immunogenicity of bivalent RSVpreF in adults 60 years of age and older in Korea.

The study duration is approximately 2 months. 4 study visits are required and are comprised of 2 scheduled clinic visits and 2 scheduled telephone calls.

Approximately 360 study-eligible participants will be randomized to receive either the 120-µg dose of RSVpreF or placebo in a 2:1 ratio.

After screening and confirmation of eligibility, a prevaccination blood sample will be collected for immunogenicity assessments and a single dose of study intervention (RSVpreF or placebo) will be administered.

Participants will report daily reactogenicity data using an electronic device for 7-days or until resolution.

Participants will return approximately 1 month later for a follow-up blood draw for immunogenicity assessments and collection of safety information.

A telephone follow-up visit will be conducted approximately 1 week after vaccination to review reactogenicity and approximately 2 months after vaccination to collect safety information.

For all participants, adverse events (AEs) will be collected from informed consent through 1 month following study intervention administration. Serious adverse events (SAEs) newly diagnosed chronic medical conditions (NDCMCs), and adverse events of special interest (AESIs) will be collected from informed consent throughout study participation.

03

Conditions studied

  • Respiratory Syncytial Virus

Keywords

  • Respiratory tract infection
  • RSV
  • Respiratory Syncytial Virus
  • Vaccine
  • Older adults
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants 60 years of age or older at Visit 1

    • Male participants able to father children must agree to use a highly effective method of from the time of through at least 28 days after study intervention administration
    • Female participants must not be of
  2. Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study.

    Healthy participants with preexisting stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included.

  3. Participants who are willing and able to comply with all scheduled visits, plan, laboratory tests, frequent symptom assessment by mobile device application (e-diary), and other study procedures.
  4. Participants who are ambulatory and live in the community, or in assisted-living or long-term care residential facilities that provide minimal assistance, such that the participant is primarily responsible for self-care and activities of daily living (ADL).
  5. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent document (ICD) and the protocol.

Exclusion criteria

Exclusion Criteria:

  1. A confirmed diagnosis of RSV infection ≤180 days before study intervention administration.
  2. Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular (IM) injection.
  3. Prior history of any subtype of Guillain-Barré syndrome (GBS) of any etiology.
  4. History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s) or any related vaccine.
  5. Serious chronic disorder, including , end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the participant from participating in the study.
  6. individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
  7. Any medical or psychiatric condition, including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality, that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  8. Individuals who receive chronic systemic treatment with immunosuppressive therapy (other than systemic meeting the criteria noted below), including cytotoxic agents, immunosuppressive monoclonal antibodies, or radiotherapy, eg, for cancer or an disease, from 60 days before study intervention administration or planned receipt throughout the study.

    • Receipt of systemic corticosteroids (≥20 mg/day of prednisone or equivalent) for

      ≥14 days from 28 days before study intervention.

    • Inhaled/nebulized, intra articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted.
  9. Receipt of blood/plasma products or immunoglobulin within 60 days before study intervention administration.
  10. Previous vaccination with any licensed or RSV vaccine, or planned receipt throughout the study.
  11. Previous administration with an investigational product (drug or vaccine) within 6 months prior to study intervention administration. Participation in other studies involving an investigational product (drug or vaccine) at any time during participation in this study.
  12. Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.

    -

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
378 participants (actual)

Study arms

  • Experimental
    RSVpreF

    Biological: RSVpreF Vaccine

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Local Reactions Within 7 Days After Vaccination

    Local reactions included redness, swelling and pain at injection site. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit=0.5 centimeter (cm). Redness and swelling were graded as mild: \> 2.0 cm to 5.0 cm, moderate: \> 5.0 cm to 10.0 cm, severe: \>10.0 cm. Pain at injection site was graded as mild: did not interfere with activity, moderate: interfered with activity, severe: prevented daily activity. Any local reaction: any redness, any swelling, or pain at the injection site of at least mild severity. Exact 2-sided 95% confidence interval (CI) was based on the Clopper and Pearson method.

    Time frame: From Day 1 to Day 7 after vaccination

  2. Percentage of Participants With Systemic Events Within 7 Days After Vaccination

    Systemic events included fever, fatigue, headache, vomiting, nausea, diarrhea, muscle pain and joint pain. Fever defined as oral temperature \>=38.0 degrees Celsius (deg C) and categorized as mild: \>=38.0 to 38.4 deg C, moderate: \>38.4 to 38.9 deg C, severe: \>38.9 to 40.0 deg C, and Grade 4: \>40.0 deg C. Vomiting categorized as mild: 1-2 times in 24 hours (h); moderate: \>2 times in 24h; severe: required intravenous (IV) hydration. Diarrhea categorized as mild: 2-3 loose stools in 24h; moderate: 4-5 loose stools in 24h; severe: 6 or more loose stools in 24h. Headache, fatigue, nausea, muscle pain and joint pain were categorized as mild: didn't interfere with activity; moderate: some interference with activity; severe: prevented daily routine activity. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

    Time frame: From Day 1 to Day 7 after vaccination

  3. Percentage of Participants With Adverse Events (AEs) From Vaccination Through 1 Month After Vaccination

    An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Exact 2-sided 95% CI was based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: From vaccination on Day 1 up to 1 month after vaccination

  4. Percentage of Participants With Serious Adverse Events (SAEs) From Vaccination Throughout the Study

    An SAE was defined as an AE that, at any dose met one of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect; was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or nonpathogenic; other significant medical events as judged by investigator. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

    Time frame: From vaccination on Day 1 up to 2 months after vaccination

  5. Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Vaccination Throughout the Study

    A NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects. Newly diagnosed chronic medical condition did not include illnesses considered to be temporary conditions. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

    Time frame: From vaccination on Day 1 up to 2 months after vaccination

  6. Geometric Mean Titer (GMT) of Neutralizing Titers (NTs) for RSV A and RSV B Before Vaccination

    GMTs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the lower limit of quantification (LLOQ) were set to 0.5\*LLOQ for analysis.

    Time frame: Before Vaccination

  7. Geometric Mean Titer (GMT) of Neutralizing Titers (NTs) for RSV A and RSV B at 1 Month After Vaccination

    GMTs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ for analysis.

    Time frame: 1 month after vaccination

  8. Geometric Mean Fold Rise (GMFR) of Neutralizing Titers (NTs) for RSV A and RSV B From Before Vaccination to 1 Month After Vaccination

    Fold rises was defined as ratios of the results after vaccination to the results before vaccination. GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution).

    Time frame: From before vaccination to 1 month after vaccination

Secondary outcomes

  1. Seroresponse Rates of Neutralizing Titers (NTs) for RSV A and RSV B at 1 Month After Vaccination

    Seroresponse rate was defined as the percentage of participants with a postvaccination NT \>=4 times the LLOQ if the baseline titer (before vaccination) was below the LLOQ; or a \>=4-fold rise from baseline if the baseline titer was\>=LLOQ. 95% CI was based on Clopper-Pearson method.

    Time frame: 1 month after vaccination

07

Results

Posted Feb 9, 2026

Participant flow

This study was conducted at 16 sites in the Republic of Korea.

Participant flow — Overall Study
MilestoneRSVpreF 120 mcgPlacebo
Started252126
Vaccinated251126
Completed250126
Not completed20
Withdrew: Protocol violation10
Withdrew: Randomized, not vaccinated10

Outcome measures

PrimaryPercentage of Participants With Local Reactions Within 7 Days After Vaccination

Local reactions included redness, swelling and pain at injection site. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit=0.5 centimeter (cm). Redness and swelling were graded as mild: \> 2.0 cm to 5.0 cm, moderate: \> 5.0 cm to 10.0 cm, severe: \>10.0 cm. Pain at injection site was graded as mild: did not interfere with activity, moderate: interfered with activity, severe: prevented daily activity. Any local reaction: any redness, any swelling, or pain at the injection site of at least mild severity. Exact 2-sided 95% confidence interval (CI) was based on the Clopper and Pearson method.

Time frame:
From Day 1 to Day 7 after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Vaccination
Percentage of participantsRSVpreF 120 mcgPlacebo
Pain at injection site: any12.4 (8.5 to 17.1)3.2 (0.9 to 7.9)
Pain at injection site: mild11.6 (7.9 to 16.2)2.4 (0.5 to 6.8)
Pain at injection site: moderate0.8 (0.1 to 2.8)0.8 (0.0 to 4.3)
Pain at injection site: severe0 (0.0 to 1.5)0 (0.0 to 2.9)
Redness: any2.8 (1.1 to 5.7)0.8 (0.0 to 4.3)
Redness: mild1.6 (0.4 to 4.0)0.8 (0.0 to 4.3)
Redness: moderate0.8 (0.1 to 2.8)0 (0.0 to 2.9)
Redness: severe0.4 (0.0 to 2.2)0 (0.0 to 2.9)
Swelling: any1.6 (0.4 to 4.0)0.8 (0.0 to 4.3)
Swelling: mild1.2 (0.2 to 3.5)0.8 (0.0 to 4.3)
Swelling: moderate0.4 (0.0 to 2.2)0 (0.0 to 2.9)
Swelling: severe0 (0.0 to 1.5)0 (0.0 to 2.9)
Any local reaction: any14.7 (10.6 to 19.7)3.2 (0.9 to 7.9)
Any local reaction: mild12.4 (8.5 to 17.1)2.4 (0.5 to 6.8)
Any local reaction: moderate2.0 (0.6 to 4.6)0.8 (0.0 to 4.3)
Any local reaction: severe0.4 (0.0 to 2.2)0 (0.0 to 2.9)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Vaccination

Systemic events included fever, fatigue, headache, vomiting, nausea, diarrhea, muscle pain and joint pain. Fever defined as oral temperature \>=38.0 degrees Celsius (deg C) and categorized as mild: \>=38.0 to 38.4 deg C, moderate: \>38.4 to 38.9 deg C, severe: \>38.9 to 40.0 deg C, and Grade 4: \>40.0 deg C. Vomiting categorized as mild: 1-2 times in 24 hours (h); moderate: \>2 times in 24h; severe: required intravenous (IV) hydration. Diarrhea categorized as mild: 2-3 loose stools in 24h; moderate: 4-5 loose stools in 24h; severe: 6 or more loose stools in 24h. Headache, fatigue, nausea, muscle pain and joint pain were categorized as mild: didn't interfere with activity; moderate: some interference with activity; severe: prevented daily routine activity. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

Time frame:
From Day 1 to Day 7 after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Vaccination
Percentage of participantsRSVpreF 120 mcgPlacebo
Fever: >=38.0°C0.4 (0.0 to 2.2)1.6 (0.2 to 5.6)
Fever: >=38.0°C to 38.4°C0 (0.0 to 1.5)1.6 (0.2 to 5.6)
Fever: >38.4°C to 38.9°C0.4 (0.0 to 2.2)0 (0.0 to 2.9)
Fever: >38.9°C to 40.0°C0 (0.0 to 1.5)0 (0.0 to 2.9)
Fever: >40.0°C0 (0.0 to 1.5)0 (0.0 to 2.9)
Fatigue: any23.1 (18.0 to 28.8)26.2 (18.8 to 34.8)
Fatigue: mild17.9 (13.4 to 23.2)15.9 (10.0 to 23.4)
Fatigue: moderate5.2 (2.8 to 8.7)10.3 (5.6 to 17.0)
Fatigue: severe0 (0.0 to 1.5)0 (0.0 to 2.9)
Headache: any12.7 (8.9 to 17.5)11.1 (6.2 to 17.9)
Headache: mild11.6 (7.9 to 16.2)8.7 (4.4 to 15.1)
Headache: moderate1.2 (0.2 to 3.5)2.4 (0.5 to 6.8)
Headache: severe0 (0.0 to 1.5)0 (0.0 to 2.9)
Muscle pain: any15.5 (11.3 to 20.6)9.5 (5.0 to 16.0)
Muscle pain: mild12.0 (8.2 to 16.6)5.6 (2.3 to 11.1)
Muscle pain: moderate3.6 (1.7 to 6.7)4.0 (1.3 to 9.0)
Muscle pain: severe0 (0.0 to 1.5)0 (0.0 to 2.9)
Joint pain: any9.2 (5.9 to 13.4)7.9 (3.9 to 14.1)
Joint pain: mild6.0 (3.4 to 9.7)4.0 (1.3 to 9.0)
Joint pain: moderate3.2 (1.4 to 6.2)4.0 (1.3 to 9.0)
Joint pain: severe0 (0.0 to 1.5)0 (0.0 to 2.9)
Nausea: any3.6 (1.7 to 6.7)6.3 (2.8 to 12.1)
Nausea: mild3.6 (1.7 to 6.7)4.0 (1.3 to 9.0)
Nausea: moderate0 (0.0 to 15)2.4 (0.5 to 6.8)
Nausea: severe0 (0.0 to 1.5)0 (0.0 to 2.9)
Vomiting: any0 (0.0 to 1.5)0.8 (0.0 to 4.3)
Vomiting: mild0 (0.0 to 1.5)0.8 (0.0 to 4.3)
Vomiting: moderate0 (0.0 to 1.5)0 (0.0 to 2.9)
Vomiting: severe0 (0.0 to 1.5)0 (0.0 to 2.9)
Diarrhea: any4.8 (2.5 to 8.2)4.0 (1.3 to 9.0)
Diarrhea: mild4.8 (2.5 to 8.2)4.0 (1.3 to 9.0)
Diarrhea: moderate0 (0.0 to 1.5)0 (0.0 to 2.9)
Diarrhea: severe0 (0.0 to 1.5)0 (0.0 to 2.9)
PrimaryPercentage of Participants With Adverse Events (AEs) From Vaccination Through 1 Month After Vaccination

An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Exact 2-sided 95% CI was based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
From vaccination on Day 1 up to 1 month after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With Adverse Events (AEs) From Vaccination Through 1 Month After Vaccination
Percentage of participantsRSVpreF 120 mcgPlacebo
Percentage of Participants With Adverse Events (AEs) From Vaccination Through 1 Month After Vaccination3.6 (1.7 to 6.7)0.8 (0.0 to 4.3)
PrimaryPercentage of Participants With Serious Adverse Events (SAEs) From Vaccination Throughout the Study

An SAE was defined as an AE that, at any dose met one of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect; was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or nonpathogenic; other significant medical events as judged by investigator. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

Time frame:
From vaccination on Day 1 up to 2 months after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With Serious Adverse Events (SAEs) From Vaccination Throughout the Study
Percentage of participantsRSVpreF 120 mcgPlacebo
Percentage of Participants With Serious Adverse Events (SAEs) From Vaccination Throughout the Study0.8 (0.1 to 2.8)0.8 (0.0 to 4.3)
PrimaryPercentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Vaccination Throughout the Study

A NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects. Newly diagnosed chronic medical condition did not include illnesses considered to be temporary conditions. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

Time frame:
From vaccination on Day 1 up to 2 months after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Vaccination Throughout the Study
Percentage of participantsRSVpreF 120 mcgPlacebo
Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Vaccination Throughout the Study1.2 (0.2 to 3.5)0 (0.0 to 2.9)
PrimaryGeometric Mean Titer (GMT) of Neutralizing Titers (NTs) for RSV A and RSV B Before Vaccination

GMTs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the lower limit of quantification (LLOQ) were set to 0.5\*LLOQ for analysis.

Time frame:
Before Vaccination
Reported as:
Geometric mean · Titer
Geometric Mean Titer (GMT) of Neutralizing Titers (NTs) for RSV A and RSV B Before Vaccination
TiterRSVpreF 120 mcgPlacebo
RSV A1472 (1326 to 1636)1617 (1402 to 1866)
RSV B1957 (1766 to 2168)1865 (1601 to 2174)
PrimaryGeometric Mean Titer (GMT) of Neutralizing Titers (NTs) for RSV A and RSV B at 1 Month After Vaccination

GMTs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ for analysis.

Time frame:
1 month after vaccination
Reported as:
Geometric mean · Titer
Geometric Mean Titer (GMT) of Neutralizing Titers (NTs) for RSV A and RSV B at 1 Month After Vaccination
TiterRSVpreF 120 mcgPlacebo
RSV A14240 (12977 to 15625)1397 (1199 to 1628)
RSV B16277 (14623 to 18117)1813 (1554 to 2115)
PrimaryGeometric Mean Fold Rise (GMFR) of Neutralizing Titers (NTs) for RSV A and RSV B From Before Vaccination to 1 Month After Vaccination

Fold rises was defined as ratios of the results after vaccination to the results before vaccination. GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution).

Time frame:
From before vaccination to 1 month after vaccination
Reported as:
Geometric mean · Fold rise
Geometric Mean Fold Rise (GMFR) of Neutralizing Titers (NTs) for RSV A and RSV B From Before Vaccination to 1 Month After Vaccination
Fold riseRSVpreF 120 mcgPlacebo
RSV A9.5 (8.51 to 10.67)0.9 (0.78 to 0.94)
RSV B8.3 (7.37 to 9.39)1.0 (0.89 to 1.06)
SecondarySeroresponse Rates of Neutralizing Titers (NTs) for RSV A and RSV B at 1 Month After Vaccination

Seroresponse rate was defined as the percentage of participants with a postvaccination NT \>=4 times the LLOQ if the baseline titer (before vaccination) was below the LLOQ; or a \>=4-fold rise from baseline if the baseline titer was\>=LLOQ. 95% CI was based on Clopper-Pearson method.

Time frame:
1 month after vaccination
Reported as:
Number · Percentage of participants
Seroresponse Rates of Neutralizing Titers (NTs) for RSV A and RSV B at 1 Month After Vaccination
Percentage of participantsRSVpreF 120 mcgPlacebo
RSV A81.0 (75.6 to 85.7)0.8 (0.0 to 4.4)
RSV B75.9 (70.1 to 81.1)0.8 (0.0 to 4.3)

Adverse events

Collected over All-cause mortality and SAEs: From vaccination on Day 1 up to 2 months after vaccination. Other AEs (non-systematic assessment): From vaccination on Day 1 up to 1 month after vaccination; Local reactions and systemic events (systematic assessment): From Day 1 to Day 7 after vaccination. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RSVpreF 120 mcg0/251 (0%)2/251 (0.8%)100/251 (39.8%)
Placebo0/126 (0%)1/126 (0.8%)43/126 (34.1%)
Most frequent serious events
Most frequent serious events
EventRSVpreF 120 mcgPlacebo
Retinal detachmentEye disorders0/2511/126
EnteritisGastrointestinal disorders1/2510/126
AsthmaRespiratory, thoracic and mediastinal disorders1/2510/126
Most frequent other events
Showing 10 of 20
Most frequent other events
EventRSVpreF 120 mcgPlacebo
Fatigue (FATIGUE)General disorders58/25133/126
Myalgia (MUSCLE PAIN)Musculoskeletal and connective tissue disorders39/25112/126
Headache (HEADACHE)Nervous system disorders32/25114/126
Injection site pain (PAIN AT INJECTION SITE)General disorders31/2514/126
Arthralgia (JOINT PAIN)Musculoskeletal and connective tissue disorders23/25110/126
Nausea (NAUSEA)Gastrointestinal disorders9/2518/126
Diarrhoea (DIARRHEA)Gastrointestinal disorders12/2515/126
Erythema (REDNESS)Skin and subcutaneous tissue disorders7/2511/126
Swelling (SWELLING)General disorders4/2511/126
Pyrexia (FEVER)General disorders1/2512/126

Baseline characteristics

Safety population included all screened participants who received the study intervention in the study.

Age, Continuous
Age, Continuous(Years)RSVpreF 120 mcgPlaceboTotal
Mean67.3 ± 5.1867.3 ± 5.1967.3 ± 5.17
Sex: Female, Male
Sex: Female, Male(Participants)RSVpreF 120 mcgPlaceboTotal
Female16876244
Male8350133
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)RSVpreF 120 mcgPlaceboTotal
Race — Asian251126377
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)RSVpreF 120 mcgPlaceboTotal
Ethnicity — Non-Hispanic/non-Latino251126377
08

Study locations

16 sites
  • Inha University Hospital
    Incheon, Incheon-gwangyeoksi [incheon] 22332, South Korea
  • Jeonbuk National University Hospital
    Jeonju, Jeonrabugdo 54907, South Korea
  • Chonnam National University Hospital
    Gwangju, Kwangju-kwangyǒkshi 61469, South Korea
  • Korea University Ansan Hospital
    Ansan-si, Kyǒnggi-do 15355, South Korea
  • Soon Chun Hyang University Bucheon Hospital
    Bucheon-si, Kyǒnggi-do 14584, South Korea
  • The Catholic University Of Korea St. Vincent's Hospital
    Suwon, Kyǒnggi-do 16247, South Korea
  • Ajou University Hospital
    Suwon, Kyǒnggi-do 16499, South Korea
  • Dong-A University Hospital
    Busan, Pusan-kwangyǒkshi 49201, South Korea
  • Severance Hospital, Yonsei University Health System
    Seoul, Seoul-teukbyeolsi [seoul] 03722, South Korea
  • Hallym University Kangdong Sacred Heart Hospital
    Seoul, Seoul-teukbyeolsi [seoul] 05355, South Korea
  • Samsung Medical Center
    Seoul, Seoul-teukbyeolsi [seoul] 06351, South Korea
  • The Catholic Univ. of Korea Seoul St. Mary's Hospital
    Seoul, Seoul-teukbyeolsi [seoul] 06591, South Korea
  • Hallym University Kangnam Sacred Heart Hospital
    Seoul, Seoul-teukbyeolsi [seoul] 07441, South Korea
  • Ewha Womans University Mokdong Hospital
    Seoul, Seoul-teukbyeolsi [seoul] 07985, South Korea
  • Korea University Guro Hospital
    Seoul, Seoul-teukbyeolsi [seoul] 08308, South Korea
  • Kyungpook National University Hospital
    Daegu, Taegu-kwangyǒkshi 41944, South Korea
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Feb 2025, 3 months.

Results were first posted in Feb 2026, 1 year after primary completion.

Of 41 phase 3 interventional studies under Respiratory Tract Infections, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 73. This study's 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2024
First posted
Sep 19, 2024
StartActual
Oct 7, 2024
Primary completionActual
Feb 3, 2025
CompletionActual
Feb 3, 2025
Results first posted
Feb 9, 2026
Last update
Feb 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06593587
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Oct 7, 2024
Primary completion
Feb 3, 2025
Completion
Feb 3, 2025
Results posted
Feb 9, 2026
Last update
Feb 9, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abrysvo

Start the discussion